TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36480111
Drug: Phenylephrine HCl
Normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine HCl (2.5 to 10 mg)
Study: 36480388
Drug: E-CPTs with
Normalized name: E-Z Scrub with Ultradex
Approvals — FDA: no, EMA: no, PMDA: no
Description: E-CPTs with 1 mL price-frame
Study: 36480395
Drug: Behavioral economic
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral economic measure drug demand
Study: 36480395
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of drug demand and LPP
Study: 36480452
Drug: Oxytocin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (0.5 to 5 IU administered as an intravenous bolus over 1 minute)
Study: 36480463
Drug: Endogenous secretory
Normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endogenous secretory leukocyte protease inhibitor (SLPI)
Study: 36481736
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg intravenously on day 1 of each 3-week cycle plus famitinib 20 mg orally once daily
Study: 36482076
Drug: Gelofusine® (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelofusine® (40 mg/ml)
Study: 36482188
Drug: Re-irradiation with
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-irradiation with a schedule of 3 Gray per fraction (minimum 18 Gy/6 fractions, maximum 30 Gy/10 fractions) with a maximum cumulative spinal dose of 100 Gy
Study: 36482193
Drug: Oral rucaparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rucaparib 600 mg twice daily
Study: 36482216
Drug: SOC +
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOC + additional rifampicin (up to 35 mg/kg/d) + linezolid 1200 mg/d reducing after 28 days to 600 mg/d
Study: 36482216
Drug: SOC +
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOC + additional rifampicin (up to 35 mg/kg/d) + linezolid 1200 mg/d reducing after 28 days to 600 mg/d + aspirin 1000 mg/d
Study: 36482352
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly injectable formulation (AOM) for 12 months
Study: 36482369
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with pulse amplitudes of 600, 700, and 800 mA
Study: 36482505
Drug: SARS-CoV-2 anti-spike
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 anti-spike antibody levels in the nose
Study: 36482505
Drug: Nasal and
Normalized name: Nasal and Sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal and saliva anti-spike antibody levels
Study: 36482505
Drug: Plasma anti-spike
Normalized name: spike lavender oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma anti-spike antibody
Study: 36482505
Drug: SARS-CoV-2 vaccine
Normalized name: SARS-CoV-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccine given peripherally
Study: 36482505
Drug: Persistently elevated
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistently elevated SARS-CoV-2 antibody in plasma
Study: 36482560
Drug: Efavirenz (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (25 mg/d for 52 weeks)
Study: 36482815
Drug: Ruxolitinib (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (15 mg twice daily) with methylprednisolone (40 mg every other day)
Study: 36483037
Drug: Therapeutic cancer
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic cancer vaccine containing peptides derived from PD-L1 and PD-L2
Study: 36483037
Drug: Therapeutic cancer
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic cancer vaccine
Study: 36483582
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies targeting the PD-1/PD-L1 signaling axis
Study: 36484484
Drug: ChAd155-RSV (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd155-RSV (low dose)
Study: 36484484
Drug: ChAd155-RSV (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd155-RSV (medium dose)
Study: 36484484
Drug: ChAd155-RSV (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAd155-RSV (high dose)
Study: 36485070
Drug: Intraperitoneal/intravenous (IP/IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal/intravenous (IP/IV) chemotherapy in HTB subgroup
Study: 36485070
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) chemotherapy in HTB subgroup
Study: 36485070
Drug: Intraperitoneal/intravenous (IP/IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal/intravenous (IP/IV) chemotherapy in LTB subgroup
Study: 36485070
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) chemotherapy in LTB subgroup
Study: 36493463
Drug: G-computation
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-computation
Study: 36493603
Drug: Self-assessment using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-assessment using a tablet application for detecting herb and food-drug interactions (HFDIs).
Study: 36494748
Drug: Ongoing evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing evidence-based assessments (annual, monthly, daily)
Study: 36494776
Drug: Assessments of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessments of caregivers' well-being and treatment decision attitudes.
Study: 36495795
Drug: Reminiscence music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence music therapy (60-minute sessions, twice a week for 4 weeks)
Study: 36496395
Drug: Serotypes included
Normalized name: Human adenovirus b serotype 7
DrugBank: Human adenovirus b serotype 7 (DB14410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotypes included in PCV13 vaccine
Study: 36498818
Drug: Anti-IL-17C monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-IL-17C monoclonal antibody MOR106, administered for up to 12 weeks.
Study: 36499023
Drug: Insulin-induced hypoglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced hypoglycemia (2 mmol/L; 36 mg/dL)
Study: 36501072
Drug: 1−2 drinks/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1−2 drinks/day (~12−24 g)
Study: 36502794
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ibuprofen
Study: 36503413
Drug: Low-dose aerosolised
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aerosolised Ad5-nCoV
Study: 36503413
Drug: High-dose aerosolised
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerosolised Ad5-nCoV
Study: 36503429
Drug: MDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT with 6 months ADT and ARTA (enzalutamide 4×40 mg daily for 6 months)
Study: 36503505
Drug: Conventional Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Wound Treatment (CWT)
Study: 36503610
Drug: Nivolumab (PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (PD-1 inhibitor) followed by SBRT (30 Gy in 3 to 5 fractions)
Study: 36503736
Drug: OCS-01 once
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OCS-01 once daily
Study: 36504158
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg and 8 mg extended-release tablets
Study: 36504158
Drug: Fesoterodine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 2 mg and 4 mg extended-release beads-in-capsule (BIC)
Study: 36504158
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg and 8 mg extended-release tablets and 4 mg BIC
Study: 36504158
Drug: Oxybutynin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin XL tablets
Study: 36504291
Drug: Verinurad 24
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 24 mg extended release with allopurinol 300 mg
Study: 36504291
Drug: Verinurad 40
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 40 mg immediate release with allopurinol 300 mg
Study: 36505793
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (vemurafenib, cobimetinib, and pembrolizumab)
Study: 36505833
Drug: Lenvatinib 8-12mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 8-12mg once daily and sintilimab 200mg once every three weeks combined with radiotherapy (3Gy*10 fraction)
Study: 36506562
Drug: SHR7280, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR7280, an oral gonadotropin-releasing hormone antagonist
Study: 36507677
Drug: Telacebec (Q203)
Normalized name: Telacebec
DrugBank: Telacebec (DB17754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telacebec (Q203) at doses of 20, 50, 100, 160, 250, and 320 mg, orally administered once daily for 14 days
Study: 36507686
Drug: Talquetamab (405
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab (405 μg per kilogram weekly)
Study: 36507686
Drug: Talquetamab (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab (800 μg per kilogram every other week)
Study: 36507690
Drug: Glofitamab monotherapy
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab monotherapy (12 cycles total) after pretreatment with obinutuzumab
Study: 36507690
Drug: Glofitamab monotherapy
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab monotherapy
Study: 36507781
Drug: Integrated boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated boost to the dominant intraprostatic nodule in stereotactic body radiation therapy, details on dosage and duration not available.
Study: 36509053
Drug: Amoxicillin (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (7-day course, standard of care)
Study: 36509063
Drug: MMV390048 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMV390048 (120 mg)
Study: 36509097
Drug: Rocatinlimab 150
Normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocatinlimab 150 mg every 4 weeks
Study: 36509097
Drug: Rocatinlimab 600
Normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocatinlimab 600 mg every 4 weeks
Study: 36509097
Drug: Rocatinlimab 300
Normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocatinlimab 300 mg every 2 weeks
Study: 36509097
Drug: Rocatinlimab 600
Normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocatinlimab 600 mg every 2 weeks
Study: 36509100
Drug: RO7020531 (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7020531 (doses: 3 mg, 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, 170 mg)
Study: 36509100
Drug: RO7020531 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7020531 (150 mg, 170 mg)
Study: 36509100
Drug: RO7020531 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7020531 (150 mg)
Study: 36509249
Drug: SB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB with twice/h breaks (alternating 5 min walk and 15 min stand)
Study: 36510290
Drug: Remimazolam tosylate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam tosylate at 0.15 mg/kg
Study: 36510290
Drug: Remimazolam tosylate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam tosylate at 0.2 mg/kg
Study: 36510290
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at 1.5 mg/kg
Study: 36510324
Drug: Ultra-lung-protective ventilation
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-lung-protective ventilation (1-2 mL/kg tidal volume, 5-10 cycles per minute, positive expiratory transpulmonary pressure, 16 hours of prone position)
Study: 39103901
Drug: Budesonide/glycopyrronium/formoterol fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 320/14.4/10 µg
Study: 36510486
Drug: Budesonide/glycopyrronium/formoterol fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) 160/14.4/10 µg
Study: 39103901
Drug: Glycopyrronium/formoterol fumarate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium/formoterol fumarate dihydrate (GFF) 14.4/10 µg
Study: 39103901
Drug: Budesonide/formoterol fumarate
Normalized name: budesonide/formoterol fumarate 80/4.5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol fumarate dihydrate (BFF) 320/10 µg
Study: 36510662
Drug: Neutralization of
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralization of ACBP/DBI through a monoclonal antibody
Study: 36511191
Drug: BI 695501
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 695501 for the entire 46-week treatment period
Study: 36511927
Drug: Self-directed, remotely
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed, remotely administered behavioral lifestyle intervention (Diabetes Prevention Program-based videos, handouts, coaching messages) for 12 months
Study: 36511927
Drug: Self-directed, remotely
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed, remotely administered behavioral lifestyle intervention
Study: 36512069
Drug: Sivopixant 50
Normalized name: Sivopixant
DrugBank: Sivopixant (DB18816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivopixant 50 mg
Study: 36512069
Drug: Sivopixant 300
Normalized name: Sivopixant
DrugBank: Sivopixant (DB18816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivopixant 300 mg
Study: 37988255
Drug: Abrocitinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrocitinib (both doses)
Study: 36512619
Drug: Evocalcet low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evocalcet low dose (1-2 mg)
Study: 36512619
Drug: Evocalcet medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evocalcet medium dose (3-4 mg)
Study: 36512619
Drug: Evocalcet high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evocalcet high dose (5-8 mg)
Study: 36512619
Drug: Evocalcet (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evocalcet (all doses)
Study: 36512671
Drug: ABBV-3373 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABBV-3373 (100 mg IV every other week for 12 weeks)
Study: 36512671
Drug: adalimumab (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab (80 mg every other week for 24 weeks)
Study: 36512738
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg once every 2 weeks plus cabozantinib 40 mg once daily (doublet arm)
Study: 36512738
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks plus cabozantinib 40 mg once daily with ipilimumab 1 mg/kg once every 6 weeks (triplet arm)
Study: 36513051
Drug: On-label reduced-dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On-label reduced-dose edoxaban
Study: 36513186
Drug: ARO-HSD 25
Normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-HSD 25 mg
Study: 36513186
Drug: ARO-HSD 100
Normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-HSD 100 mg
Study: 36513186
Drug: ARO-HSD 200
Normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-HSD 200 mg
Study: 36513449
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (136.6 mg as aglycone equivalents)
Study: 36513490
Drug: Porcine protein
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine protein supplement (twice a day for 6 weeks)
Study: 36513490
Drug: Maltodextrin supplement
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin supplement (twice a day for 6 weeks)
Study: 36513815
Drug: Pressurized intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with Cisplatin (7.5 mg/m2)
Study: 36513991
Drug: Immunotherapy (anti-PD1/PDL1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (anti-PD1/PDL1 or anti-CTLA4 monotherapy or combination therapy)
Study: 36514019
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg tablets taken three times a day)
Study: 36514143
Drug: Variable dose
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable dose anticoagulation
Study: 36514248
Drug: Benzodiazepine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine and Z-drugs (BZDRs) use
Study: 36514248
Drug: BZDRs daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZDRs daily use with increasing doses
Study: 36514730
Drug: Integrated palliative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated palliative care visits (monthly for 3 months)
Study: 36514850
Drug: Risankizumab 75
Normalized name: risankizumab 75 mg/0.83 mL subcutaneous kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 75 mg
Study: 36514850
Drug: Risankizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (both doses)
Study: 36515491
Drug: Continuous intrathecal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrathecal infusion of bupivacaine combined with low-dose fentanyl
Study: 36515785
Drug: Physical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical and functional well-being measured by the Functional Assessment of Cancer Therapy-General
Study: 36515888
Drug: Probiotic BC30
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic BC30 with a 20-g dose of a blend of rice and pea protein
Study: 36515888
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20-g dose of a blend of rice and pea protein without BC30)
Study: 36515980
Drug: OmniGraf monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OmniGraf monitoring in conjunction with medication-related symptom burden (MRSB) monitoring
Study: 36516076
Drug: Chlorthalidone at
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone at a daily dose of 12.5 or 25 mg
Study: 36516076
Drug: Hydrochlorothiazide at
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide at a daily dose of 25 or 50 mg
Study: 36516082
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving B-cell-directed therapy
Study: 36516343
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine (0.5-0.75 mg/kg)
Study: 36517097
Drug: Breathing exercise
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing exercise (BE) intervention; 4-week self-administered program
Study: 36517235
Drug: Mirogabalin 10
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 10 or 15 mg BID for 12 weeks
Study: 36517235
Drug: Mirogabalin 5
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 5 mg BID for 1 week, 10 mg BID for 1 week
Study: 36517469
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of BNT162b2
Study: 36517740
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard antibiotic therapy without PCT monitoring)
Study: 36517767
Drug: Erenumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (140 mg)
Study: 36517865
Drug: AV-GBM-1 vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-GBM-1 vaccine administration
Study: 36518248
Drug: ctDNA-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA-guided therapy
Study: 36518253
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor letrozole (2.5mg/day; n=11)
Study: 36518253
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone (1mg/kg/every 4 weeks; n=11)
Study: 36518729
Drug: Scheduled, simultaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled, simultaneous doses of acetaminophen, celecoxib, and pregabalin; oxycodone 5 mg as needed for breakthrough pain.
Study: 36518729
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and oxycodone 5 mg/acetaminophen 325 mg as needed for pain (Control).
Study: 36518987
Drug: Serum progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serum progesterone levels ≥7.8 ng/ml
Study: 36518987
Drug: Serum progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Serum progesterone levels <7.8 ng/ml